Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.47 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.36 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.36 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.36 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.36 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.36 |
| ▸ | IL1RN | P18510 | 2/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23355920 | 1.00 | IL1RN (0.47) | IL1RNERAP2ERAP1ACHEKDM1A | |
| Hydrochloric Acid SCHEMBL29984305 | 1.00 | IL1RN (0.47) | IL1RNERAP2ERAP1ACHEKDM1A | |
| Hydrochloric Acid SCHEMBL2167605 | 1.00 | IL1RN (0.47) | IL1RNERAP2ERAP1ACHEKDM1A | |
| SCHEMBL1150600 | 0.98 | IL1RN (0.49) | IL1RNERAP2ERAP1ACHEKDM1A | |
| SCHEMBL12402720 | 0.98 | IL1RN (0.49) | IL1RNERAP2ERAP1ACHEKDM1A | |
| SCHEMBL1879560 | 0.98 | IL1RN (0.49) | IL1RNERAP2ERAP1ACHEKDM1A | |
| Hydrochloric Acid SCHEMBL29145483 | 0.89 | KDM1A (0.42) | IL1RNERAP2ERAP1ACHEKDM1A | |
| Hydrochloric Acid SCHEMBL30302232 | 0.89 | KDM1A (0.42) | IL1RNERAP2ERAP1ACHEKDM1A | |
| SCHEMBL17193124 | 0.87 | GID4 (0.42) | IL1RNERAP2ERAP1ACHEKDM1A | |
| SCHEMBL29983834 | 0.87 | GID4 (0.42) | IL1RNERAP2ERAP1ACHEKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234030-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12269812-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| CN-118221646-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-112399874-B | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4313968-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2024-02-07 | — | — | EP | disclosed |
| CN-117412959-A | Substituted 1-aryl-1 '-heteroaryl compounds, substituted 1,1' -biaryl compounds, and methods of use thereof | 爱彼特生物制药公司 | 2024-01-16 | — | — | CN | disclosed |
| EP-4234030-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3820572-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-112399874-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2021-02-23 | — | — | CN | disclosed |
| US-20210024494-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10774071-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200017471-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-01-16 | — | — | US | disclosed |
| EP-2706999-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2019-08-28 | — | — | EP | disclosed |
| EP-2498609-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2018-04-18 | — | — | EP | disclosed |
| US-9481659-B2 | Selective heterocyclic sphingosine 1 phosphate receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2016-11-01 | — | — | US | disclosed |
| US-20150299179-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150252037-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2015-09-10 | — | — | US | disclosed |
| US-20140039183-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2014-02-06 | — | — | US | disclosed |
| US-8507538-B2 | Selective heterocyclic sphingosine 1 phosphate receptor modulators | RECEPTOS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110183953-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774071-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | ACHE 3411/4885HTR2C 4331/4885HTR2B 4572/4885 |
| US-12269812-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | ACHE 3411/4885HTR2C 4331/4885HTR2B 4572/4885 |
| US-20140039183-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | ACHE 4017/4885HTR2C 331/4885HTR2B 507/4885 |
| US-20150252037-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | ACHE 4017/4885HTR2C 331/4885HTR2B 507/4885 |
| US-20150299179-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | ACHE 4014/4885HTR2C 333/4885HTR2B 503/4885 |
| US-20200017471-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | ACHE 3411/4885HTR2C 4331/4885HTR2B 4572/4885 |
| US-20210024494-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | ACHE 3411/4885HTR2C 4331/4885HTR2B 4572/4885 |
| US-20110183953-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | ACHE 4014/4885HTR2C 333/4885HTR2B 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.